Valerie Larouche
Quebec, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications
Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.
Journal: Nature communications
Published: October 09, 2025
Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 07, 2025
Integrated clinical and molecular landscape of disseminated pediatric low-grade glioma.
Journal: Neuro-oncology
Published: June 11, 2025
Severe Hearing Loss in Children With Central Nervous System Tumors: A Population-Based Cancer in Young People in Canada (CYP-C) Report.
Journal: Pediatric blood & cancer
Published: May 07, 2025
Disseminated pediatric low-grade glioma and hydrocephalus: a multinational consortium analysis of incidence and mortality.
Journal: Journal of neurosurgery. Pediatrics
Published: April 25, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Journal: Nature medicine
Published: April 16, 2025
Salvage therapies for first relapse of SHH medulloblastoma in early childhood.
Journal: Neuro-oncology
Published: April 05, 2025
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.
Journal: Nature communications
Published: September 02, 2024
Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas.
Journal: Current oncology (Toronto, Ont.)
Published: June 03, 2024
Epidemiology of Pediatric Tumors in Quebec: A 17-Year Report of Cancer in Young People in the Canada Registry.
Journal: Current oncology (Toronto, Ont.)
Published: March 13, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
Journal: Nature medicine
Published: March 12, 2024
Last Updated: 09/26/2026